WBB Securities upgraded its rating of Affymax (NASDAQ:AFFY) from Buy to Strong Buy and changed its price target to $8. The shares recently traded at $4.89, up $0.23, or 4.94%, on the day. The shares have traded in a 52-week range of $3.93 to $8.50, and its market capitalization is $173.86 million. About the company: Affymax Inc. is a clinical-stage biopharmaceutical company. The Company develops peptide-based drugs for the treatment of serious and life-threatening conditions such as kidney disease and cancer.
Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>